Category and buyer
This is institutional growth funding led by long-term capital pools. Scottish Widows and Aberdeen Investments, alongside IP Group, are backing four UK deeptech companies, where the buyer is effectively a pension and asset management complex paying for exposure to venture-style innovation and potential outsize equity outcomes.
The deal
Scottish Widows, Aberdeen Investments and IP Group have invested in Oxford Quantum Circuits, Quantum Motion, Nyobolt and Genomics Limited, according to Tech.eu. Financial terms were not disclosed.
The funding spans technology-led businesses with long development cycles and high technical risk. Two of the four targets are in quantum computing, while Nyobolt is focused on advanced battery technology and Genomics Limited operates in genomics-driven health tech.
Why this matters
For UK deeptech, the signal is not the ticket size but the source of capital. Pension-linked investors and large asset managers are structurally different from traditional early-stage venture funds.
- Time horizon and patience: Deeptech companies often need years of R&D, specialist hiring, and iterative prototyping before commercial scale. Capital with a longer duration can reduce the risk of “funding cliffs” that force premature go-to-market moves.
- Governance and diligence intensity: Institutional investors typically require tighter reporting, risk controls, and clearer pathways to commercial validation. That can professionalise scaling plans, but it can also lengthen financing and decision cycles.
- Follow-on capacity: When deeptech programmes work, they often require repeated, larger rounds to fund engineering, manufacturing ramp, and customer deployment. Investors with larger balance sheets can be a better fit for those step-ups, provided mandates allow for follow-on exposure.
Company angle: four different commercialisation paths
With limited disclosed information on round structure, the most useful lens is how each category tends to monetise and what will likely drive retention and expansion if product-market fit lands.
Quantum (Oxford Quantum Circuits, Quantum Motion)
Quantum computing companies typically face a two-track commercialisation challenge: sustaining long R&D cycles while building credible near-term revenue signals.
Likely retention and expansion drivers include:
- Deep technical integration with partner ecosystems (cloud access, tooling, developer environments) that creates switching costs.
- Procurement credibility with enterprise and public-sector buyers where security, uptime, and roadmap certainty matter.
- Milestone-based financing tied to technical benchmarks (performance, error correction progress, scalability) that can influence valuation and access to follow-on capital.
Advanced batteries (Nyobolt)
Battery innovation tends to be constrained by manufacturing realities: scale-up, supply chain qualification, and customer validation cycles.
Commercial drivers typically include:
- Qualification lock-in once customers certify cells or systems into products.
- Channel strategy through OEM partnerships and integrators rather than purely direct sales.
- Capex discipline: moving from lab to pilot to scaled production is capital intensive, and execution risk is high.
Genomics-driven health tech (Genomics Limited)
Genomics businesses often monetize through clinical decision support, risk scoring, or partnerships with healthcare systems and insurers.
Typical GTM and retention drivers include:
- Evidence and regulatory pathway that supports adoption in clinical workflows.
- Workflow embed in provider systems, where implementation depth and training drive stickiness.
- Pricing power linked to demonstrated clinical utility and downstream cost reduction.
Strategic lens: what IP Group adds
With IP Group participating, the round also reflects the UK’s recurring model of venture-building around research commercialisation. In deeptech, capital is only one input. Operator support around recruiting, partnerships, and structuring follow-on rounds can materially change outcomes, especially where companies must balance scientific milestones with early customer traction.
Outlook
With terms undisclosed, the near-term read-through is that UK deeptech continues to broaden its funding base beyond specialist venture funds. The operational question is whether these companies can translate patient capital into repeatable commercial motions, not just technical progress.
What this enables
- Longer runway for R&D-heavy roadmaps without forcing premature revenue compromises
- Stronger follow-on capacity if milestones are met
- More structured governance and reporting, which can improve later-round readiness
- Increased credibility when negotiating strategic partnerships
What to watch
- Whether future rounds include larger institutional allocations or revert to specialist VC
- Commercial milestones: pilots converting into multi-year contracts and repeatable deployments
- Manufacturing and scale-up risk for hardware-heavy programmes
- How quickly each company can build a durable GTM engine alongside technical execution